Female reproductive dysfunction in familial Mediterranean fever patients with and without colchicine treatment

Sirs,

Familial Mediterranean fever (FMF) is an autosomal-recessive inherited disease characterised by recurrent episodes of fever, abdominal pain and serositis. Colchicine is effective in preventing attacks that can be stimulated by various stimuli such as stress, cold exposure or infections. In the literature there are many evidences about FMF and female reproductive system dysfunctions: ovarian failure and efficacy of colchicine in infertility prevention, due to ovarian dysfunction and peritoneal adhesions, are described (1-3). It has also been reported an increase of spontaneous abortion incidences in FMF-affected women two-fold more than the general population (25-30% vs. 15%) (4-6). Indeed, frequent peritonitis, as seen in untreated or unresponsive-to-treatment FMF, may determine premature uterine contractions with abortion risk or premature birth (2, 3, 7).

We aimed to verify the prevalence and type of infertility among FMF women, and the prevalence of spontaneous abotions and premature deliveries in FMF patients with or without colchicine treatment.

We evaluated, retrospectively, a cohort of female patients diagnosed with FMF at our Periodic Fever Research Center between January 1998 and July 2008. A questionnaire was administered to obtain data concerning the presence and type of infertility (if studied), number of pregnancies carried to term, progress and therapy taken during pregnancy, the presence and type of infertility (if studied), number of pregnancies carried to term, progress and therapy taken during pregnancy, and pregnancy complications and congenital malformations.

Among 221 FMF patients, there were 108 women, of whom 78 in fertile age and therefore eligible for our study. Thirty-eight women, of whom 73 in fertile age and 15 years of age, were treated with colchicine (the first one occurred two weeks after amniocentesis. There were 2 premature deliveries in 2 women with FMF symptoms but not in colchicine: 1 patient because of drug-resistance, 3 patients were doubtful regarding drug side-effects, and all others because they had been not diagnosed as FMF yet. In this last group, 38/48 (79%) pregnancies were carried to term, and 10/48 (21%) ended in miscarriage at different periods of pregnancy. None of those patients had diabetes or other conditions associated with miscarriage. Among 6 patients treated with colchicine, there were 9 pregnancies: 8 carried to term, and only one abortion occurred two weeks after amniocentesis. There were 2 premature deliveries in 2 patients treated with colchicine (the first one had a gestosis, the other showed placental abnormality). There were no foetus malformations in the group of patients in therapy or in those without it.

In our study, the infertility prevalence was about two-fold compared to the general population (20% vs. 8-10%) (8; the largest number of pregnancies (48/61) occurred without colchicine and 21% of them ended in miscarriage, with an increased prevalence compared to the general population (10-15%) as already reported in pre-colchicine era data (4-5). Those observations might be due to the considerable diagnosis and treatment delay in Italy (14.8 years). Thus, we can assume that the lack of therapy over a long period of time increases the risk of infertility/abortions compared to the general population. Another interesting issue arising from this study is the absence of congenital foetus malformations in patient groups under colchicine treatment; therefore colchicine seems, currently, a relatively safe drug that should be continued throughout pregnancy (9).

Further studies with a larger FMF population would be helpful in confirming those data.

C. CERQUAGLIA, MD
E. VERRECCHIA, MD
C. FONNESU, MD
G. GIOVINALE, MD
A. MARINARO, MD
G. DI SÒCO, MD
R. MANNA, MD, PhD

Periodic Fever Research Center, Department of Internal Medicine, A. Gemelli Policlinic, Rome, Italy.

Address correspondence to: Rafaele Manna, MD, Periodic Fever Center, Department of Internal Medicine, A. Gemelli Policlinic, Largo A. Gemelli 8, 00168 Rome, Italy.
E-mail: rmannu@rm.unical.it

Competing interests: none declared.

References
6. ISRAEL P, ZEMER D, DUKAI E, SOHAR E: Further studies with a larger FMF population would be helpful in confirming those data.